TrialTargeted oncology2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Maya Gottfried et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this paperpooled itcites it